“Specifically Targeting Interleukin-13 With Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients With Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 5, no. 1, Jan. 2021, p. s9, https://doi.org/10.25251/skin.5.supp.9.